

## Mouse IL-22 ELISA Kit

**Catalog Number: RK00108**

This ELISA kit used for quantitative determination of mouse Interleukin 22 (IL-22) concentrations in cell culture supernates, serum and plasma. For research use only, and it's highly recommended to read throughly of this manual before using the product.

### Manufactured by

**Global Headquarters**

**500W Cummings Park**

**Ste. 6500 Woburn, MA 01801**

**Tel :888-754-5670**

**E-mail:info@abclonal.com**

**http: www.abclonal.com**

**China Branch**

**388# Gaoxin Road (No.2)**

**East Lake Development Zone**

**Wuhan P. R. China**

**Tel: 400-999-6126**

**E-mail: market@abclonal.com**

**http: www.abclonal.com.cn**

## Contents

<b>Introduction</b> .....	2
<b>Principle Of The Assay</b> .....	5
<b>Materials Provided</b> .....	6
<b>Sample Collection And Storage</b> .....	7
<b>Precautions For Use</b> .....	8
<b>Experiment Materials</b> .....	9
<b>Reagent Preparation</b> .....	10
<b>Wash Method</b> .....	13
<b>Assay Procedure</b> .....	13
<b>Assay Procedure Summary</b> .....	14
<b>Calculation Of Results</b> .....	16
<b>Typical Data</b> .....	17
<b>Sensitivity</b> .....	17
<b>Specificity</b> .....	18
<b>Precision</b> .....	19
<b>Recovery</b> .....	20
<b>Linearity Dilute</b> .....	20
<b>References</b> .....	20

## Introduction

IL-22/TIF(IL-10-related T cell-derived inducible factor) is a new cytokine originally identified as a gene induced by IL-9 in murine T lymphocytes, and showing 22% amino acid identity with IL-10. In the mouse, the IL-22 gene is located on chromosome 10, in the same region as the IFN gamma gene. Although it is a single copy gene in BALB/c and DBA/2 mice, the IL-22 gene is duplicated in other strains such as C57Bl/6, FVB and 129. The two copies, which show 98% nucleotide identity in the coding region, were named IL-TIF alpha and IL-TIF beta with the IL-TIF beta gene being either differentially regulated, or not expressed at all.

IL-22 is produced by activated Th1 and NK cells acting primarily on epithelial cells and is involved in inflammatory responses. Neither resting nor activated immune cells express IL-22 receptor, and IL-22 does not have any effects on these cells in vitro and in vivo. In contrast, cells of the skin and the digestive and respiratory systems represent putative targets of this cytokine. Thus IL-22 does not serve the communication between immune cells but is a T cell mediator that directly promotes the innate, nonspecific immunity of tissues. IL-22 serves as a protective molecule to counteract the destructive nature of the immune response to limit tissue damage.

Interleukin-22 (IL-22) is a cytokine that regulates the production of acute phase proteins of the immunological response. On binding to its cognate receptor (IL-22R1), which is associated to the interleukin-10 receptor 2 (IL-10R2), IL-22 promotes activation of signal transducer and activator of transcription (STAT) pathway and several other cellular responses. A soluble receptor termed interleukin-22 binding protein (IL-22BP) is also able to bind to IL-22 as a natural

protein antagonist, and probably provides systemic regulation of IL-22 activity. IL-22, in contrast to its relative IFN gamma, regulates the expression of only a few genes in keratinocytes. This is due to varied signal transduction. The IL-22 effects are transcriptional and either BMS6022 and BMS6022TEN mouse IL-22 4 independent of protein synthesis and secretion, or mediated by a secreted protein. Inflammatory conditions, but not keratinocyte differentiation, amplify the IL-22 effects. IL-22 application in mice enhances cutaneous S100A9 and MMP1 expression.

Psoriatic patients show strongly elevated IL-22 plasma levels, which correlated with the disease severity. IL-22 plays a protective role in T cell-mediated hepatitis induced by Concanavalin A (Con A), acting as a survival factor for hepatocytes. IL-22 is present in high quantities in the blood of Crohn's disease patients in contrast to IFN gamma and IL-17.

## Principle Of The Assay

This assay employs the quantitative sandwich enzyme immunoassay technique. A monoclonal antibody specific for IL-22 has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any IL-22 present is bound by the immobilized antibody. Following incubation unbound samples are removed during a wash step, and then a detection antibody specific for IL-22 is added to the wells and binds to the combination of capture antibody-IL-22 in sample. Following a wash to remove any unbound combination, and enzyme conjugate is added to the wells. Following incubation and wash steps, a substrate is added. A colored product TMB is formed in proportion to the amount of IL-22 present in the sample. The reaction is terminated by addition of acid and absorbance is measured. A standard curve is prepared from seven IL-22 standard dilutions and IL-22 sample concentration determined.

## Materials Provided

Part	Size (96T)	Cat NO.	STORAGE OF OPENED/ RECONSTITUTED MATERIAL
Antibody Coated Plate	8×12	RM00460	Return unused wells to the foil pouch containing the desiccant pack and store at ≤ -20 °C. Reseal along entire edge of zip-seal.
Standard Lyophilized	3	RM00457	Aliquot and store at ≤ -20 °C in a manual defrost freezer.* Avoid repeated freeze-thaw cycles.
Concentrated Biotin Conjugate Antibody (30×)	1 ×400ul	RM00458	May be stored for up to 6 month at 2-8 °C.*
Streptavidin-HRP Concentrated (30×)	1 ×400ul	RM00459	
Standard/Sample Diluent (R1)	1 ×20mL	RM00023	May be stored for up to 6 month at 2-8 °C.*
Biotin-Conjugate Antibody Diluent (R2)	1 ×16mL	RM00024	
Streptavidin-HRP Diluent(R3)	1 ×16mL	RM00025	
Wash Buffer(20x)	1 × 30mL	RM00026	
TMB Substrate	1 ×12mL	RM00027	

<b>Stop Solution</b>	<b>1 ×12mL</b>	<b>RM00028</b>	
<b>Plate Sealers</b>	<b>4 strips</b>		
<b>Specification</b>	<b>1</b>		

## Sample Collection And Storage

### 1. Cell Culture Supernates:

Centrifuge 1000x g for 10 min and detect; or aliquot and store samples at -20°C to -70°C (Stored at 2-8°C if tested within 24 hours). Avoid freeze/thaw cycles. If cell culture supernate samples require larger dilutions, perform an intermediate dilution with culture media and the final dilution with the Standard/Sample Diluent(R1).

### 2. Serum:

Use a serum separator tube and allow samples to clot for 30 minutes before centrifugation for 10 minutes at 1000x g, and detect; or aliquot and store samples at -20°C to -70°C (Stored at 2-8°C if tested within 24 hours). Avoid freeze/thaw cycles.

### 3. Plasma

Collect plasma using EDTA or heparin as an anticoagulant. Centrifuge for 15 minutes at 1000x g within 30 minutes of collection, and detect; or aliquot and store samples at -20°C to -70°C (Stored at 2-8°C if tested within 24 hours). Avoid freeze / thaw cycles.

### 4. Avoid hemolytic and hyperlipidemia sample for Serum and Plasma.

### 5. Dilution:

Dilute samples at the appropriate multiple (recommend to do pre-test to determine the dilution factor).

## Precautions

1. **FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.**
2. Any variation in diluent, operator, pipetting technique, washing technique, incubation time or temperature, and kit age can cause variation in binding.
3. Variations in sample collection, processing, and storage may cause sample value differences.
4. Reagents may be harmful, if ingested, rinse it with an excess amount of tap water.
5. Stop Solution contains strong acid. Wear eye, hand, and face protection.
6. Apart from the standard of kits, other components should not be refrigerated.
7. Please perform simple centrifugation to collect the liquid before use.
8. Do not mix or substitute reagents with those from other lots or other sources.
9. Adequate mixing is very important for good result. Use a mini-vortexer at the lowest frequency.
10. Mix the sample and all components in the kits adequately, and use clean plastic container to prepare all of the diluent.
11. Both the sample and standard should be assayed in duplicate, and the sequence of the reagents should be added consistently.
12. Reuse of dissolved standard is not recommended.

13. The kit should not be used beyond the expiration date on the kit label.
14. The kit should be away from light when it is stored or incubated.
15. To reduce the likelihood of blood-borne transmission of infectious agents, handle all serum, plasma and other biological fluids in accordance with NCCLS regulations.
16. To avoid cross contamination, please use disposable pipette tips.
17. Please prepare all the kit components according to the Specification. If the kits will be used several times, please seal the rest strips and preserve with desiccants. Do use up within 2 months.
18. The 48T kit is also suitable for the specification.


## Experiment Materials

1. Microplate reader(measuring absorbance at 450 nm, with the correction wavelength set at 570 nm or 630 nm).
2. Pipettes and pipette tips: 0.5-10, 2-20, 20-200, 200-1000  $\mu$ L.
3. Microplate washer, Squirt bottle.
4. Micro-oscillator.
5. Deionized or double distilled water, graduated cylinder.
6. Polypropylene Test tubes for dilution.
7. Incubator.

## Reagent Preparation

- 1. Bring all reagents to room temperature before use. If crystals have formed in the concentrate, Bring the reagent to room temperature and mix gently until the crystals have completely dissolved.**
- 2. Standard:** Add Standard/Sample Diluent(R1) 1.0mL into freeze-dried standard, sit for a minimum of 15 minutes with gentle agitation prior to making dilutions (6000pg/mL), Prepare EP tubes containing Standard/Sample Diluent(R1), and produce a dilution series according to the picture shown below (recommended concentration for standard curve: 3000, 1500, 750, 375, 187.5, 93.75, 46.88, 0 pg/mL). Redissolved standard solution (6000 pg/mL), aliquot and store at -20°C— -70°C.

Std 250  $\mu$ L      250  $\mu$ L



R1 Std 1000 $\mu$ L	R1 250 $\mu$ L						
6000 pg/mL	3000pg/mL	1500pg/mL	750pg/mL	375pg/mL	187.5pg/mL	93.75pg/mL	46.88pg/mL

- 3. Concentrated Biotin Conjugate Antibody (30x)** : Dilute 1:30 with the Biotin-Conjugate Antibody Diluent (R2) before use, and the diluted solution should be used within 30 min.

### Dilution Method

Strip	Concentrated Biotin-Conjugate antibody (30x)	Biotin-Conjugate Antibody Diluent (R2)
2	66 $\mu$ L	1914 $\mu$ L
4	132 $\mu$ L	3828 $\mu$ L
6	198 $\mu$ L	5742 $\mu$ L
8	264 $\mu$ L	7656 $\mu$ L
10	330 $\mu$ L	9570 $\mu$ L
12	396 $\mu$ L	11484 $\mu$ L

4. **Streptavidin-HRP Concentrated (30x):** Dilute 1:30 with the Streptavidin-HRP Diluent(R3) before use, and the diluted solution should be used within 30 min.

### Dilution Method

Strip	Concentrated Streptavidin-HRP (30x)	Streptavidin-HRP Diluent(R3)
2	66uL	1914uL
4	132uL	3828uL
6	198uL	5742uL
8	264uL	7656uL
10	330uL	9570uL
12	396uL	11484uL

5. **Wash buffer:** Dilute 1:20 with double distilled or deionized water before use.

## Wash Method

Aspirate each well and wash, repeating the process two times for a total of three washes. Wash by filling each well with **Wash Buffer**(300ul) using a squirt bottle, manifold dispenser, or autowasher. Complete removal of liquid at each step is essential to good performance. After the last wash, remove any remaining **Wash Buffer** by aspirating or decanting. Invert the plate and blot it against clean paper towels.


## Assay Procedure

1. Remove excess microplate strips from the plate frame, return them to the foil pouch containing the desiccant pack, and reseal.
2. Add 100  $\mu$ L Standard/sample Diluent (R1) in blank well.
3. Add 100  $\mu$ L different concentration of standard and sample in other wells, cover with the adhesive strip provided. Incubate for 1.5 hours at 37°C.
4. Add wash buffer 300  $\mu$ L/well, aspirate each well after holding 40 seconds, repeating the process four times for a total of five washes.
5. Prepare the Concentrated Biotin Conjugate Antibody (30X) Working Solution 15 minutes early before use.
6. Add Biotin-Conjugate antibody Working Solution in each wells (100 $\mu$ L/well), cover with new adhesive strip provided. Incubate for 1 hour at 37°C.
7. Prepare the Streptavidin-HRP Concentrated (30X) Working Solution

15minutes early before use.

8. Repeat the aspiration/wash as in step 4.
9. Add Streptavidin-HRP Working Solution in each wells (100  $\mu$ L/well), cover with new adhesive strip provided. Incubate for 30 minutes at 37°C.
10. Warm-up the Microplate reader.
11. Repeat the aspiration/wash as in step 4.
12. Add TMB Substrate (100 $\mu$ L/well). Incubate for 15-20 minutes at 37°C .Protect from light.
13. Add Stop Solution (100 $\mu$ L/well), determine the optical density of each well within 5 minutes, using a Microplate reader set to 450 nm. If wavelength correction is available, set to 570 nm or 630 nm. If wavelength correction is not available, subtract readings at 570 nm or 630 nm from the readings at 450 nm. This subtraction will correct for optical imperfections in the plate. Readings made directly at 450 nm without correction may be higher and less accurate.

## Assay Procedure Summary



*Incubate for 30 min at 37°C* ↓ *wash 3 times*

**Add 100ul Substrate Solution**

*Incubate for 15-20 min* ↓ *at 37°C under dark condition.*

**Add 100ul Stop Solution**


**Detect the optical density within 5 minutes under 450nm.**

**Correction Wavelength set at 570nm or 630nm**

## Calculation Of Results

1. Average the duplicate readings for each standard, control and sample, and subtract the average zero standard optical density (O.D.).
2. Create a standard curve by reducing the data using computer software capable of generating a log/log curve-fit. As an alternative, construct a standard curve by plotting the mean absorbance for each standard on the y-axis against the concentration on the x-axis and draw a best fit curve through the points on a log/log graph. The data may be linearized by plotting the log of the IL-22 concentrations versus the log of the O.D. on a linear scale, and the best fit line can be determined by regression analysis.
3. If samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.

## Typical Data



The standard curves are provided for demonstration only. A standard curve should be generated for each set of IL22 assayed.

## Sensitivity

The minimum detectable dose (MDD) of IL22 is typically less than 23.4 pg/mL. The MDD was determined by adding two standard deviations to the mean optical density value of twenty zero standard replicates and calculating the corresponding concentration.

## Specificity

This assay recognizes both recombinant and natural mouse IL-22. The factors listed below were prepared at 50ng/ml and assayed for cross-reactivity. No significant cross-reactivity was observed with the following:

Recombinant human:

IL-10

IL-11

IL-12p40

IL-18

IL-23

## Precision

### Intra-plate Precision

Three samples of known concentration were tested 20 times on one plate to evaluate the Intra-plate precision.

<b>Sample</b>	<b>1</b>	<b>2</b>	<b>3</b>
<b>Repeat Times</b>	<b>20</b>	<b>20</b>	<b>20</b>
<b>Average Value (pg/mL)</b>	<b>25</b>	<b>150</b>	<b>300</b>
<b>Standard Deviation (SD)</b>	<b>0.87</b>	<b>6.2</b>	<b>10.8</b>
<b>Variable Coefficient CV (%)</b>	<b>3.5</b>	<b>4.1</b>	<b>3.6</b>

### Inter-plate Precision

Three samples of known concentration were tested 20 times separate assays to evaluate the Inter-plate precision. Assays were using two lots of components.

<b>Sample</b>	<b>1</b>	<b>2</b>	<b>3</b>
<b>Repeat Times</b>	<b>20</b>	<b>20</b>	<b>20</b>
<b>Average Value (pg/mL)</b>	<b>30</b>	<b>155</b>	<b>310</b>
<b>Standard Deviation (SD)</b>	<b>2.0</b>	<b>11.1</b>	<b>19.8</b>
<b>Variable Coefficient CV (%)</b>	<b>6.8</b>	<b>7.2</b>	<b>6.4</b>

## Recovery

Spike 3 different concentration of mouse IL-22 into healthy mouse serum and plasma, calculate the recovery.

Sample Form	Average Recover (%)	Range (%)
Serum	96	89-112
Plasma	95	90-105

## Linearity

Spike high concentration of mouse IL-22 into 4 healthy mouse serum, dilute in the range of standard curve kinetics and evaluate the linearity.

Dilution	Average Value (%)	Range (%)
1:2	98	86-103
1:4	97	90-115
1:8	98	85-106
1:16	99	92-108

## References

1. Dumoutier, L. et al. (2000) *J. Immunol.* 164:1814.
2. Gurney, A.L. (2004) *Int. Immunopharmacol.* 4:669.
3. Wolk, K. et al. (2006) *Eur. J. Immunol.* 36:1309.
4. Dumoutier, L. et al. (2000) *Genes Immun.* 1:488.
5. Nagem, R.A.P. et al. (2002) *Structure* 10:1051.
6. Nagalakshmi, M.L. et al. (2004) *Int. Immunopharmacol.* 4:679.
7. Wolk, K. and R. Sabat (2006) *Cytokine and Growth Factor Reviews* 17:367.
8. Liang, S.C. et al. (2006) *J. Exp. Med.* 203:2271.
9. Xie, M-H. et al. (2000) *J. Biol. Chem.* 275:31335.
10. Li, J. et al. (2004) *Int. Immunopharmacol.* 4:693.
11. Kotenko, S.V. and J.A. Langer (2004) *Int. Immunopharmacol.* 4:593.
12. Kotenko, S.V. et al. (2001) *J. Biol. Chem.* 276:2725.
13. Tachiiri, A. et al. (2003) *Genes Immun.* 4:153.
14. Spencer, S.D. et al. (1998) *J. Exp. Med.* 187:571.
15. Dumoutier, L. et al. (2000) *Proc. Natl. Acad. Sci. USA* 97:10144.
16. Wolk, K. et al. (2004) *Immunity* 21:241.
17. Nagalakshmi, M.L. et al. (2004) *Int. Immunopharmacol.* 4:577.
18. Wei, C-C. et al. (2003) *Genes Immun.* 4:204.
19. Weiss, B. et al. (2004) *Genes Immun.* 5:330.
20. Radaeva, S. et al. (2004) *Hepatology* 39:1332.
21. Aggarwal, S. et al. (2001) *J. Interf. Cytokine Res.* 21:1047.